Literature DB >> 32055269

Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy.

Ledi Kuang1,2, Yuedong He1,2.   

Abstract

V-domain Ig suppressor of T-cell activation (VISTA), which belongs to the B7 family and is expressed predominantly on hematopoetic cells, myeloid, granulocytic and T cells, can suppresses T-cell activation in vivo and vitro. The blockade of VISTA has displayed brilliant results in certain murine tumor models. But to date, little is known about the expression and impact of VISTA in human cervical cancer (CC). To fill this gap of information, we systemically investigated the expression of VISTA on tumor cells, intratumoral immune cells (ICs) and vascular endothelial cells (VECs) in a group of patients with CC by performing immunohistochemical analysis. The associations between VISTA expression and different clinicopathologic features were evaluated using Fisher's exact test, and the analysis of overall survival in different groups was performed by the construction of Kaplan-Meier models. The results indicated that high expression of VISTA on ICs or VECs was significantly related to advanced tumor stage and the lymph node metastasis (LNM) of CC. Furthermore, we performed multivariate Cox regression analysis, which showed that there was no association between VISTA expression and the 5-year overall survival rate, and LNM was the only independent predicting factor of poor prognosis for CC. IJCEP
Copyright © 2020.

Entities:  

Keywords:  V-domain immunoglobulin suppressor of T cell activation; cervical cancer; immune checkpoint; immunohistochemical staining; immunotherapy; overall survival analysis

Year:  2020        PMID: 32055269      PMCID: PMC7013368     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  22 in total

Review 1.  The current status of immunotherapy for cervical cancer.

Authors:  Cecilia Orbegoso; Krithika Murali; Susana Banerjee
Journal:  Rep Pract Oncol Radiother       Date:  2018-05-18

2.  A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix.

Authors:  Walayat Shah; Xiaofei Yan; Li Jing; Yi Zhou; Hongwei Chen; Yili Wang
Journal:  Cell Mol Immunol       Date:  2010-11-22       Impact factor: 11.530

Review 3.  PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives.

Authors:  Yumeng Wang; Guiling Li
Journal:  Front Med       Date:  2019-03-02       Impact factor: 4.592

4.  Dehydrocostus Lactone Inhibits Proliferation, Antiapoptosis, and Invasion of Cervical Cancer Cells Through PI3K/Akt Signaling Pathway.

Authors:  Enping Jiang; Xiwen Sun; Haixian Kang; Liping Sun; Weifang An; Yunhong Yao; Xinrong Hu
Journal:  Int J Gynecol Cancer       Date:  2015-09       Impact factor: 3.437

5.  Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.

Authors:  Yuta Kondo; Tatsukuni Ohno; Naoto Nishii; Kiyoshi Harada; Hideo Yagita; Miyuki Azuma
Journal:  Oral Oncol       Date:  2016-05-03       Impact factor: 5.337

6.  Lin28B is a novel prognostic marker in gastric adenocarcinoma.

Authors:  Qian Hu; Jing Peng; Weiping Liu; Xiaoli He; Ling Cui; Xinlian Chen; Mei Yang; Hongqian Liu; Shanling Liu; He Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

7.  VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.

Authors:  Li Wang; Rotem Rubinstein; Janet L Lines; Anna Wasiuk; Cory Ahonen; Yanxia Guo; Li-Fan Lu; David Gondek; Yan Wang; Roy A Fava; Andras Fiser; Steve Almo; Randolph J Noelle
Journal:  J Exp Med       Date:  2011-03-07       Impact factor: 14.307

8.  Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression-based study.

Authors:  Yongfu Xiong; Kang Wang; He Zhou; Linglong Peng; Wenxian You; Zhongxue Fu
Journal:  Cancer Med       Date:  2018-08-16       Impact factor: 4.452

9.  VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

Authors:  J Louise Lines; Lorenzo F Sempere; Thomas Broughton; Li Wang; Randolph Noelle
Journal:  Cancer Immunol Res       Date:  2014-06       Impact factor: 11.151

10.  VISTA is an immune checkpoint molecule for human T cells.

Authors:  J Louise Lines; Eirini Pantazi; Justin Mak; Lorenzo F Sempere; Li Wang; Samuel O'Connell; Sabrina Ceeraz; Arief A Suriawinata; Shaofeng Yan; Marc S Ernstoff; Randolph Noelle
Journal:  Cancer Res       Date:  2014-04-01       Impact factor: 12.701

View more
  2 in total

Review 1.  IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy.

Authors:  Xi-Yang Tang; Yan-Lu Xiong; Xian-Gui Shi; Ya-Bo Zhao; An-Ping Shi; Kai-Fu Zheng; Yu-Jian Liu; Tao Jiang; Nan Ma; Jin-Bo Zhao
Journal:  Biomark Res       Date:  2022-07-13

2.  Effect of CMNa combined with radiotherapy on the tumor immune microenvironment of mouse cervical cancer cell transplantation tumor model.

Authors:  Li Li; Weiqiang Shi; Juying Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.